Cardiovascular diseases (CVD) are responsible for more deaths than any other disease, continue to threaten the quality of life for many, and is a major burden to the health care system. The Framingham Heart Study (FHS) identified the major CVD risk factors that became essential to effective CVD screening strategies and the Framingham Risk Score (FRS), is used to assess CVD risk. Based on the concepts of the health behavior model and CVD as a cardiometabolic disorder, multivariate logistic regression analysis was used to evaluate the association between fasting blood glucose (FBG) levels and a CHD event, and to determine the value of FBG replacing a diagnosis of diabetes (DM2) in the FRS. The data set consisted of the 2,677 subjects of the FHS III cohort. In the univariate analysis, both DM2 and FBG were statistically significant (both p =.000), but the association was stronger for DM2, b = 2.138, OR = 8.483 (95% CI: 4.229, 17.105) than for FBG, b = .015, p = .000, OR=1.015 (95% CI: 1.009, 1.022). When adjusted for age, blood pressure, cholesterol, and smoking status, only DM2 remained statistically significant, OR = 2.295, p = .041, (95% CI: 1.035, 5.087) in the model. The FBG version of the FRS did not provide any improvement in performance, as it was marginally inferior to the DM2 version. Furthermore, the interactions between FBG and the metabolic risk factors were not statistically significant for this given data set. The results imply that a diagnosis of diabetes remains the factor of choice for inclusion in the FRS model for predicting the 10-year risk of CHD and replacing it with FBG provides little to no practical benefit. These findings support the use of CVD risk factor reduction and the use of effective screening tools in CVD prevention and promotion heart health.

Este estudo teve por objetivo avaliar a prevalência de doença periodontal e risco de doença cardiovascular estratificado pelos métodos de Framingham e PROCAM em uma amostra de sujeitos do Instituto Dante Pazzanese de Cardiologia. Trata-se de um estudo de prevalência com 56 sujeitos do gênero masculino de 45 a 70 anos dos Ambulatórios de Coronariopatia e Cardiologia do Esporte que aceitaram participar voluntariamente e tiveram os dados coletados da anamnese, do exame clínico global e periodontal e de análises laboratoriais. Os parâmetros clínicos periodontais foram: Registro Periodontal Simplificado (PSR), Índice Comunitário de Necessidades de Tratamento Periodontal (CPITN), Índice de Placa (IP), Índice de sangramento sulcular à sondagem (IS), Profundidade de Sondagem (PS), nível de inserção clínica periodontal (NIC) e Retração Gengival (RG). Avaliaram-se também na anamnese e no exame clínico global a idade, etnia, escolaridade, estado civil, hábitos alimentares, pressão arterial pulsátil, índice de massa corpórea (IMC), tabagismo, histórico familiar de cardiopatias, atividade física semanal e presença de doenças sistêmicas. Na avaliação laboratorial analisamos Glicemia, Triglicérides, Lipoproteína de Alta (HDL) e Baixa (LDL) Densidade, Colesterol Total e Proteína C Reativa. Os dados laboratoriais e clínicos foram utilizados como base de cálculo do logaritmo de estratificação de risco de doença cardiovascular nos métodos de Framingham e PROCAM. Foi então realizada a análise univariada e de freqüência para cada dado coletado, como também foi analisada a correlação entre os métodos periodontais e de estratificação de risco de doença cardiovascular. Finalizando com a análise de correlação da prevalência de doença periodontal com o risco de doença cardiovascular. Foi estabelecido o nível de significância de 5%. Os sujeitos do ambulatório de Coronariopatia apresentaram maior risco de doença cardiovascular calculado pelos métodos de Framingham e PROCAM (T1=1,212, p=0,048; T1=1,843, p=0,045), índice de massa corporal e concentração plasmática de proteína C reativa, menor intervalo de temporal de atividade física semanal do que os sujeitos do ambulatório de Cardiologia do Esporte. Nos parâmetros periodontais os sujeitos do ambulatório de Coronariopatia apresentaram maior freqüência de periodontite moderada no exame de PSR, maior índice de placa, índice de sangramento sulcular, perda de inserção clínica e profundidade de sondagem do que nos sujeitos do ambulatório de Cardiologia do Esporte. A prevalência de doença periodontal foi significantemente maior nos sujeitos com maior risco de doença cardiovascular estratificado nos métodos de Framingham e PROCAM (r=0,786/Framingham; r=0,823/PROCAM). / Oral infection models have emerged as useful tools to study the hypothesis that infection and inflammatory reaction is a independent cardiovascular disease (CVD) risk factor. Periodontal infections are a leading culprit, with studies reporting associations between periodontal disease and CVD, but this studies the periodontal diagnosis and coronary risk show substantial variations. This study aimed to analyze the different methods of periodontal diagnosis (Periodontal Screening and Recording - PSR and Clinical Attachment Loss - CAL) and correlation with Framingham and PROCAM coronary risk. The result shown strong and significant associations between periodontal diagnosis (r=0,812) and coronary risk (r=0,786/Framingham; r=0,823/PROCAM). Evidence continues to support an association among periodontal infections, atherosclerosis and vascular disease in different periodontal diagnosis and coronary risk stratification methods.

Este estudo teve por objetivo avaliar a prevalência de doença periodontal e risco de doença cardiovascular estratificado pelos métodos de Framingham e PROCAM em uma amostra de sujeitos do Instituto Dante Pazzanese de Cardiologia. Trata-se de um estudo de prevalência com 56 sujeitos do gênero masculino de 45 a 70 anos dos Ambulatórios de Coronariopatia e Cardiologia do Esporte que aceitaram participar voluntariamente e tiveram os dados coletados da anamnese, do exame clínico global e periodontal e de análises laboratoriais. Os parâmetros clínicos periodontais foram: Registro Periodontal Simplificado (PSR), Índice Comunitário de Necessidades de Tratamento Periodontal (CPITN), Índice de Placa (IP), Índice de sangramento sulcular à sondagem (IS), Profundidade de Sondagem (PS), nível de inserção clínica periodontal (NIC) e Retração Gengival (RG). Avaliaram-se também na anamnese e no exame clínico global a idade, etnia, escolaridade, estado civil, hábitos alimentares, pressão arterial pulsátil, índice de massa corpórea (IMC), tabagismo, histórico familiar de cardiopatias, atividade física semanal e presença de doenças sistêmicas. Na avaliação laboratorial analisamos Glicemia, Triglicérides, Lipoproteína de Alta (HDL) e Baixa (LDL) Densidade, Colesterol Total e Proteína C Reativa. Os dados laboratoriais e clínicos foram utilizados como base de cálculo do logaritmo de estratificação de risco de doença cardiovascular nos métodos de Framingham e PROCAM. Foi então realizada a análise univariada e de freqüência para cada dado coletado, como também foi analisada a correlação entre os métodos periodontais e de estratificação de risco de doença cardiovascular. Finalizando com a análise de correlação da prevalência de doença periodontal com o risco de doença cardiovascular. Foi estabelecido o nível de significância de 5%. Os sujeitos do ambulatório de Coronariopatia apresentaram maior risco de doença cardiovascular calculado pelos métodos de Framingham e PROCAM (T1=1,212, p=0,048; T1=1,843, p=0,045), índice de massa corporal e concentração plasmática de proteína C reativa, menor intervalo de temporal de atividade física semanal do que os sujeitos do ambulatório de Cardiologia do Esporte. Nos parâmetros periodontais os sujeitos do ambulatório de Coronariopatia apresentaram maior freqüência de periodontite moderada no exame de PSR, maior índice de placa, índice de sangramento sulcular, perda de inserção clínica e profundidade de sondagem do que nos sujeitos do ambulatório de Cardiologia do Esporte. A prevalência de doença periodontal foi significantemente maior nos sujeitos com maior risco de doença cardiovascular estratificado nos métodos de Framingham e PROCAM (r=0,786/Framingham; r=0,823/PROCAM). / Oral infection models have emerged as useful tools to study the hypothesis that infection and inflammatory reaction is a independent cardiovascular disease (CVD) risk factor. Periodontal infections are a leading culprit, with studies reporting associations between periodontal disease and CVD, but this studies the periodontal diagnosis and coronary risk show substantial variations. This study aimed to analyze the different methods of periodontal diagnosis (Periodontal Screening and Recording - PSR and Clinical Attachment Loss - CAL) and correlation with Framingham and PROCAM coronary risk. The result shown strong and significant associations between periodontal diagnosis (r=0,812) and coronary risk (r=0,786/Framingham; r=0,823/PROCAM). Evidence continues to support an association among periodontal infections, atherosclerosis and vascular disease in different periodontal diagnosis and coronary risk stratification methods.

Submitted by Irene Nascimento (irene.kessia@ufpe.br) on 2016-12-15T14:53:15Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) VersaoAtualizada2016 - Tese Georgge Gomes Oliveira - varsão para biblioteca UFPE.pdf: 3290385 bytes, checksum: 2ddc23c4486bcc121a9ea222566d1f09 (MD5) / Made available in DSpace on 2016-12-15T14:53:15Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) VersaoAtualizada2016 - Tese Georgge Gomes Oliveira - varsão para biblioteca UFPE.pdf: 3290385 bytes, checksum: 2ddc23c4486bcc121a9ea222566d1f09 (MD5) Previous issue date: 2015-04-27 / Ministério da Saúde do Brasil / Estudos recentes mostram que a síndrome metabólica (SM) é freqüente nas pessoas vivendo com HIV/AIDS (PLWHA). A importância na identificação da SM baseia-se no aumento do risco em cinco vezes de desenvolver diabetes mellitus tipo 2 (DM2) e em duas vezes de apresentar doença cardiovascular (DCV) trombóticas, embora os fatores de hipercoagulabilidade não estejam incluídos nos critérios de definição da síndrome. A SM é caracterizada pela presença concomitante de fatores reconhecidamente aterogênicos em um mesmo indivíduo. A freqüência de DCV em PLWHA vem aumentando ao longo dos anos. O PAI-1 é uma proteína importante na cascata de fibrinólise e seu aumento está associado ao estado de hipercoagulabilidade. Sua regulação depende de fatores genéticos, dentre eles, destaca-se o polimorfismo 4G5G do gene SERPINE1. A participação de substâncias protrombóticas na doença cardiovascular é conhecida em pessoas sem HIV, porém menos elucidada em PLWHA. Diante disto o objetivo deste trabalho foi determinar a freqüência do polimorfismo 4G5G em pessoas que vivem com HIV e verificar se o polimorfismo tem associação com a expressão do PAI-1 plasmático, com SM e com risco cardiovascular (RCV) estimado pelo escore de Framingham. Também objetivamos verificar associação dos níveis de PAI-1 com RDC e com SM. Para tanto foi desenvolvido estudo transversal para determinação da freqüência do polimorfismo 4G5G do PAI-1 e estudo tipo caso-controle para verificar associações entre polimorfismos com níveis plasmáticos de PAI-1 com SM e depois com RCV. Também foram testadas associações com fatores de risco tradicionais. Para primeiro estudo a amostra foi 185 pessoas sorteadas de um grupo de 2074 participantes da Cohort AIDS-PE Study Group. A prevalência de heterozigose foi de 86,8% e homozigose para 4G4G de 4,4%. A média de idade foi de 40,5 (DP ± 9,9 anos). A mediana de PAI-1 ativado foi de 13,6 ng/mL (IQ: 10,8-17,5). A freqüência de SM foi de 37,9% e de dislipidemia de 82,4%. Não encontramos associação do polimorfismo com os níveis plasmáticos de PAI-1, nem com SM. Para o segundo estudo houve perda de 23, restando 162 pessoas das quais 72,8% era do sexo feminino e a média de idade foi de 40 anos. A freqüência de RDCV estimado > 10% foi de 10,5%. O alelo 4G esteve presente em 91,0% das pessoas (genótipos 4G4G e 4G5G). Não houve associação entre polimorfismo e RDCV estimado > 10% (OR=0,6; IC95% 0,1 – 3,7), nem diferença dos níveis de PAI-1 em relação ao RDCV estimado (RCV>10% 14,6 ng/ml x RDCV < 10% 14,1 ng/ml; ρ=0,9). Hipercolesterolemia foi associada com genótipo 5G5G do polimorfismo (OR: 3,3; IC95%: 1,25 – 10) e com níveis plasmáticos mais elevados do PAI-1 (colesterol não HDL (CNHDL) > 130 mg/dl = 15,6 ng/ml versus CNHDL < 130 ng/ml = 13,8 ng/ml; ρ=0,04). Nesse estudo, encontramos alta prevalência do heterozigose para o polimorfismo 4G5G em pessoas vivendo com HIV/AIDS, no nordeste do Brasil. Entretanto, não encontramos associação entre o polimorfismo estudado com níveis plasmáticos de PAI-1 nem com SM. Também não verificamos associação do polimorfismo 4G5G do PAI-1 nem dos níveis plasmáticos de PAI-1 com RCV>10% pelo escore de Framingham, mas houve com hipercolesterolemia. / Recent studies show that the metabolic syndrome (MS) is common in people living with HIV / AIDS (PLWHA). The importance of identifying MS is based on an increased risk of developing fivefold type 2 diabetes mellitus (T2DM) and twice presenting cardiovascular disease (CVD) thrombotic, although hypercoagulability factors are not included in the definition of criteria syndrome. MS is characterized by the concomitant presence of known atherogenic factors in the same individual. The frequency of CVD in PLWHA has increased over the years. The PAI-1 is an important protein in the fibrinolytic cascade and its increase is associated with the hypercoagulable state. Its regulation depends on genetic factors, among them stands out the 4G5G polymorphism SERPINE1 gene. The participation of prothrombotic substances in cardiovascular disease is known in people without HIV, but less elucidated in PLWHA. In view of this the objective of this study was to determine the frequency of 4G5G polymorphism in people living with HIV and verify that polymorphism is associated with the expression of PAI-1 plasma with MS and cardiovascular risk (RCVD) estimated by the Framingham score . We aim to also assess the association of PAI- 1 levels with CVD and with MS. For this cross-sectional study was developed to determine the frequency of 4G5G polymorphism of PAI- 1 and case-control study to examine associations between polymorphisms and plasma levels of PAI- 1 with SM and then RCVD. Associations were also tested with traditional risk factors. For the first study sample was randomly selected 185 people of a group of participants 2074 of AIDS-PE Cohort Study Group. The prevalence of heterozygosity was 86.8% and homozygous for 4G4G 4.4%. The average age was 40.5 (SD ± 9.9 years). The PAI-1 activated median was 13.6 ng/mL (CI: 10.8 to 17.5). The frequency of MS was 37.9% and 82.4% dyslipidemia. We did not find polymorphism association with plasma levels of PAI-1 or with SM. For the second study, there was loss of 23, leaving 162 people of which 72.8% were female and the average age was 40 years. The frequency of RDCV estimated> 10% was 10.5%. The 4G allele was present in 91.0% of people (4G4G and 4G5G genotypes). There was no association between polymorphism and RDCV estimated> 10% (OR = 0.6; 95% CI 0.1 to 3.7), or difference of PAI-1 levels relative to estimated RDCV (RCV> 10% 14.6 ng / ml x RDCV <10% 14.1 ng/ml; ρ = 0.9). Hypercholesterolemia was associated with 5G5G genotype polymorphism (OR: 3.3; 95% CI: 1.25 to 10) and higher plasma levels of PAI-1 (non-HDL cholesterol (CNHDL)> 130 mg / dl = 15.6 ng/ml CNHDL versus <130 ng/ml = 13.8 ng/ ml; ρ = 0.04). In this study, we found a high prevalence of heterozygous for the polymorphism 4G5G in people living with HIV/AIDS, in northeastern Brazil. However, we found no association between the polymorphism studied with plasma levels of PAI-1 or with SM. Nor do we find polymorphism association 4G5G of PAI-1 or plasma levels of PAI-1 with RCV> 10% by Framingham score, but happened to hypercholesterolemia.

Submitted by Franciele Moreira (francielemoreyra@gmail.com) on 2017-11-21T17:24:03Z No. of bitstreams: 2 Tese - Max Weyler Nery - 2013.pdf: 3823648 bytes, checksum: 45da627ca3fc33274b6ed62abbaf86f2 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-11-22T10:12:26Z (GMT) No. of bitstreams: 2 Tese - Max Weyler Nery - 2013.pdf: 3823648 bytes, checksum: 45da627ca3fc33274b6ed62abbaf86f2 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2017-11-22T10:12:26Z (GMT). No. of bitstreams: 2 Tese - Max Weyler Nery - 2013.pdf: 3823648 bytes, checksum: 45da627ca3fc33274b6ed62abbaf86f2 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2013-05-16 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / A highly active antiretroviral therapy (HAART) has significantly reduced the morbidity and mortality of HIV infection. The greatest survival, chronic inflammation and metabolic changes resulting from HAART are associated with increased cardiovascular disease (CVD). Objectives: To evaluate the correlation between CVD risk scores; estimate the frequency of evaluating the metabolic and obtaining lipid targets in HIV-positive patients. Method: Cohort of seropositive individuals recruited at a referral center for HIV, in Goiás, 2009-2011. 294 participants aged >19 years were followed with clinical and laboratory evaluations performed at baseline, after 3 and 6 months. We analyzed the correlation between Framingham with and without aggravating factors; PROCAM and DAD (Kappa). We estimated the frequency of metabolic changes and obtaining lipid targets, post-intervention, according to Guidelines of the Brazilian Society of Cardiology. According to clinical and laboratory criteria, patients received rosuvastina and/or ciprofibrate. The level of significance was set at p<5%. SPSS 18.0 software was used. Results: predominantly male population (76.9%); with a mean age of 36.8 years (SD=10.3); 66.3% on HAART, of whom 50.0% for less than two years. High risk of CVD ranged from 0.4 to 5.7%. Intermediate risk for CVD was seen in 3.2, according to the Framingham score and 39.9% of the participants, considering the presence of aggravating factors. At baseline, 72.8% of participants had some type of dyslipidemia. There was a significant reduction in the percentage of individuals with mixed dyslipidemia and low HDL, post-deployment lipid targets (p<0.05). Conclusions: Framingham with aggravating factors seems to overestimate cardiovascular risk in HIV positive patients. One third of patients with dyslipidemia reached lipid treatment targets in six months. Further studies are needed to assess the predictive power of different risk scores, as well as to assess the benefits of medium and long-term use of statins in this population. / A terapia antirretroviral (TARV) potente reduziu de forma significativa a morbidade e a mortalidade da infecção pelo HIV. A maior sobrevida, o processo inflamatório crônico e as alterações metabólicas decorrentes da TARV estão associados a um aumento de doenças cardiovasculares (DCV). Objetivos: Avaliar a concordância entre escores de risco para DCV; estimar a frequência de alterações metabólicas e avaliar a obtenção de metas lipídicas, em pacientes HIV positivos. Método: Coorte de indivíduos soropositivos recrutados em centro de referência para HIV, em Goiás, de 2009 a 2011. Foram acompanhados 294 participantes com idade > 19 anos, sendo realizadas avaliações clínicas e laboratoriais na admissão, após 3 e 6 meses. Analisou-se a concordância entre: Framingham, com e sem fatores agravantes; PROCAM e DAD (Kappa). Estimou-se a frequência de alterações metabólicas e de obtenção de metas lipídicas, pós-intervenção, segundo a IV Diretriz da Sociedade Brasileira de Cardiologia. De acordo com critérios clínicos e laboratoriais, os pacientes receberam rosuvastina e/ou ciprofibrato. O nível de significância foi estabelecido em p<5%. Utilizou-se o programa SPSS 18.0. Resultados: População predominantemente masculina (76,9%); com média de idade de 36,8 anos (desvio padrão=10,3); 66,3% em uso de TARV, dos quais 50,0% há menos de dois anos. Alto risco para DCV variou de 0,4 a 5,7%. Risco intermediário para DCV foi evidenciado em 3,2, segundo o escore de Framingham e em 39,9% dos participantes, considerando a presença de fatores agravantes. Na avaliação inicial, 72,8% dos participantes apresentavam algum tipo de dislipidemia. Observou-se uma redução significativa do percentual de indivíduos com dislipidemias mistas e com HDL-baixo, pós-implantação de metas lipídicas (p<0,05). Conclusões: Framingham com fatores agravantes parece superestimar o risco cardiovascular em pacientes HIV positivos. Um terço dos pacientes com dislipidemias alcançou as metas terapêuticas lipídicas, em seis meses. Novos estudos são necessários para avaliar o poder de predição dos diferentes escores de risco, bem como para avaliar os benefícios à médio e longo prazo do uso de hipolipemiantes, nessa população.

The objective of this dissertation is to develop and evaluate quantitative models that have the potential to improve cardiovascular disease (CVD) screening and projection efforts in the U.S. Paper 1 assesses the exchangeability of a non-laboratory-based CVD risk score (predictors do not include cholesterol) with more commonly-used laboratory-based scores, such as the Framingham risk equations. Under conventional thresholds for identifying high-risk individuals, 92-96% of adults in the National Health and Nutrition Examination Survey (NHANES III) were equivalently characterized as high- or low-risk using either type of score. The 10-year CVD death results also suggest that simple CVD risk assessment could be a useful proxy for more expensive laboratory-based screening strategies in the U.S. or other resource-limited settings. Paper 2 uses micro-simulation modeling techniques to evaluate the cost effectiveness of primary cardiovascular disease (CVD) screening using staged laboratory-based and/or non-laboratory-based total CVD risk assessment. The results imply that efficient screening guidelines should include non-laboratory-based risk assessment, either as a single stage or as part of multistage screening approach. Compared to current CVD screening guidelines, fewer cholesterol tests would be administered and more adults would receive low-cost statins under cost-effective screening policies. Paper 3 examines the trends of CVD risk factors, treatment, and total risk in the U.S. from 1973-2010, and offers projections of these variables for 2015-2030. Nine waves of cross-sectional NHANES data show that the divergent, observed trends in common CVD risk factors (such as smoking, BMI, total cholesterol, and blood pressure) are expected to continue in future years. Age-adjusted CVD risk has decreased over time (during the observed and projected periods), but total risk has increased when considering the impact of aging on CVD risk. Scenario analyses suggest that strategies targeting cholesterol and blood pressure treatment have the greatest potential to reduce future CVD burden in the U.S.

Objetivo: El objetivo del estudio es determinar la concordancia entre las escalas PROCAM (Prospective Cardiovascular Münster) y Framingham en pacientes receptores de Tratamiento Antirretroviral de Gran Actividad (TARGA). Método: Estudio transversal analítico en población masculina VIH positiva receptora de TARGA dentro de un hospital de referencia nacional ubicado en Lima, Perú. Para evaluar la concordancia entre ambas escalas se empleó el método gráfico de Bland y Altman, correlación con el coeficiente de Pearson y acuerdo entre pruebas mediante el coeficiente de Kappa. Resultados: Enrolamos 111 personas, con edad promedio de 47,0 años. El 76,6% presentó dislipidemia. Los triglicéridos evidenciaron una media de 265,0 mg/dL. La distribución de pacientes en riesgo cardiovascular bajo, moderado y alto fue de 81,2%, 13,6% y 5,4%, según PROCAM y de 71,2%, 25,2% y 3,6% según Framingham respectivamente. Según el método de Bland y Altman, la concordancia fue adecuada en valores bajos y se fue perdiendo en riesgos altos. El coeficiente de Pearson mostró fuerte correlación (r=0,87 y P<0,05) y el coeficiente de Kappa fue de 0,56 (p<0,001). Conclusiones: La concordancia existente a riesgos bajos se va perdiendo a medida que el riesgo se va incrementando. Existe fuerte correlación entre ambas escalas. Se recomienda realizar más estudios que permitan conocer qué escala es la más óptima para ser utilizada en población adulta VIH positiva receptora de TARGA. / Objective: The aim of the study is to determine the concordance between the PROCAM (Prospective Cardiovascular Münster) and Framingham scales in patients receiving highly active antiretroviral therapy (HAART). Method: A cross sectional study was conducted in HIV-positive male population who use HAART in a national reference hospital located in Lima, Peru. To evaluate the concordance between the two scales the graphic method of Bland and Altman was used, for the evaluation of the correlation we used the Pearson coefficient and to measure the agreement we use the kappa coefficient. Results: 111 patients were enrolled, with an average age of 47.0 years. The 76.6% had dyslipidemia. Triglycerides showed an average of 265.0 mg/dL. The distribution of patients according to the risk was low, moderate and high, 81.2%, 13.6% and 5.4% respectively for PROCAM and 71.2%, 25.2% and 3.6% for Framingham. According to the graphic method of Bland and Altman, the concordance was adequate in low values and was lost as the risk score increased. Pearson's test found a strong correlation (r = 0.87 and P <0.05) and the kappa coefficient was 0.56 (p<0,001). Conclusions: The agreement we found at low risk decreases as the risk increases. Strong correlation was found between the two scales. We recommend further studies in order to know which scale of cardiovascular risk is the most optimal scale for clinical practice among HIV population who receive HAART.

BACKGROUND: The prevalence of Alzheimer’s disease (AD) and other types of dementia is expected to drastically increase between now and midcentury because of the aging baby boomer population. It is projected that by 2030, 74 million people aged 65 and older will comprise nearly 20% of the population (United States Census Bureau, 2017). By 2060, it is estimated that about 13.8 million people will have AD. In 2020, the estimated total health care costs for treating individuals with AD in 2020 is $305 billion (Wong, 2020). As the population ages, the cost is expected to increase to more than $1 trillion. This significant economic and health care burden could be greatly alleviated by the development of a treatment that would delay the onset of the disease or prevent the disease altogether. Increasing evidence supports cardiovascular health being linked to the health of the brain. Diabetes is a particular risk factor that increases the likelihood of cardiovascular disease and is consequently associated with a higher risk of developing AD and other dementias. AIM: The aim of this study was to determine the association between persistent high blood glucose during midlife to late life and the risk of incident dementia and AD. METHODS: This study included 1287 Framingham Offspring participants (669 women, mean age 68.6 ± 5.7 years) who were free of dementia and attended 5 consecutive examinations at 4-year intervals starting at midlife (Exam 3: 1983–1987, mean age 54.6 ± 5.8 years) until late life (Exam 7: 1998–2001, mean age 68.6 ± 5.7 years). These participants were subsequently followed up for incident dementia after a period of time (mean 14 ± 4.5 years). Based on the resulting data, this study examined the effect of midlife diabetes (fasting blood glucose level ≥ 126 mg/dL), late-life diabetes, 10-mg/dL incremental increases in fasting blood glucose (FBG), persistence of diabetes during midlife to late life, and a steep increase in FBG from midlife to late life over an 18-year exposure period. Further stratified analysis was completed on a subgroup of participants with a steep incline in FBG to determine if there was an interaction effect with apolipoprotein E4 (APOE4) carrier status. RESULTS: During the follow-up period, 172 participants developed dementia, and of these cases, 135 participants had AD. Multivariable Cox proportional hazards models showed that persistent high FBG was associated with greater than 2-fold increase in risk of both incident dementia (hazard ratio [HR] 2.13, 95% confidence interval [CI] 1.37-3.33) and AD ([HR] 2.18, 95% [CI] 1.33-3.57) after adjusting for age, sex, education, APOE4, prevalent cardiovascular disease (CVD), and midlife diabetes treatment. In addition, individuals who experienced a steep increase in their FBG from Exam 3 to Exam 7 were associated with an increased risk of developing AD (p value = 0.022). Further stratification by APOE4 carrier status with a steep increase in FBG revealed that APOE4 non-carriers were associated with an approximate 2-fold increased risk for developing incident dementia ([HR] 1.90, 95% [CI] 1.12-3.16; p value < 0.05) and AD ([HR] 2.30, 95% [CI] 1.28-4.06; p value < 0.05). CONCLUSIONS: Persistent high blood glucose was associated with an increased risk for developing incident dementia and AD in a community-based cohort. A steep increase in FBG during midlife to late life also increased the risk for developing dementia and AD in this cohort. These data support the potential of sustained cognitive benefits from lower blood glucose levels in midlife but also suggest that sharp increases in blood glucose levels in older adults may be a risk marker for dementia and AD.

No description available.

Introdução: As doenças cardiovasculares constituem a principal causa demorbimortalidade nacional. Nesse sentido realizou-se estudo com o objetivo de caracterizar o perfil para riscos cardiovasculares em motoristas profissionais de transporte de cargas que trafegam pela Br-116. Casuística e Método: Estudo transversal, descritivo e exploratório com 258 motoristas profissionais de transporte de cargas com obtenção de informações socioeconômicas; avaliações antropométricas: índice de massa corporal (IMC), circunferência abdominal e medida da pressão arterial; realização de exames laboratoriais: triglicérides, colesterol total e frações, proteína C reativa e creatinina. Analisou-se o risco para doenças cardiovasculares pelo Escore de Risco de Framingham, consumo de bebidas alcoólicas pelo Alcohol Use Disorders Identification-AUDIT, distúrbios psiquiátricos comuns pelo Self Report Questionnaire-SRQ-20, Síndrome Metabólica e angina pectoris pelo Teste de Rose. Os dados foram processados no sistema SPSS v.7.5. O nível de significância adotado foi p<0,05, utilizou-se análise univariada e multivariada. Resultados: A caracterização os motoristas estudados mostrou idade 37,5±10,1 anos, 91% de etnia branca, renda mensal 1.431,3±644,4 reais, 19% tabagistas, 55% referiram ingestão de bebidas alcoólicas, 74% não realizavam atividade físicas, 14% relataram uso de medicamentos inibidores do sono, tempo profissão de 14±10 anos e percorriam 782,9±229,6 km/dia, dirigiam 10 horas por dia e repousavam 06 horas diárias. Verificou-se pelos dados antropométricos que 46% tinham sobrepeso, 36% obesidade e 58% circunferência abdominal alterada (_94 cm). Os exames laboratoriais mostraram 33% com nível de colesterol total _ 200mg/dL, 10% LDL-c _ 160 mg/dL; HDL-c < 40 mg/dL 23%, triglicérides acima de 150 mg/dL 38%, glicemia _ 110mg/dL 7% e proteína C reativa > 0,5 mg/dL 19%, creatinina >1,5 mg/dL 1%. A prevalência da hipertensão arterial foi de 37% e da Síndrome metabólica 24%. O Questionnaire Rose foi positivo em 8,0% dos motoristas, Escore de Risco de Framingham médio/alto em 9%, presença de distúrbios psiquiátricos comuns em 33% e AUDIT 16% no escore que sugere intervenção e aconselhamento. A análise de regressão logística indicou associação independente para as seguintes variáveis (OD Odds ratio, IC intervalo de confiança a 95%): 1-Síndrome Metabólica: IMC (OR=1,40 IC 1,192-1,661); hábito de verificar o colesterol total (OR= 0,102 IC 0,017-0,589); e escore de risco de Framingham médio/alto (OR= 26,389 IC 2,520-276,374). 2-Hipertensão arterial: IMC (OR=1,183 IC 1,065-1,314); glicemia (OR=1,039 IC 1,004-1,076); e hábito de ingerir medicamento para inibir o sono (OR= 0,322 IC 0,129-0,801). 3- Colesterol Total (_ 200 mg/dL): LDL-c (OR=1,157 IC 1,100-1,216);triglicérides (OR=1,012 IC 1,004-1,021) 4- Glicemia (_ 110 mg/dL): IMC (OR=1,153 IC 1,024-1,298); maior tempo de profissão (OR=1,154 IC 1,057-1,259) 5-Proteína C reativa (>0,5 mg/dL): escore de risco de Framingham médio/alto (OR=4,692 IC 1,912-11,515). Conclusão: Verificou-se presença expressiva de fatores de risco cardiovasculares, nesse sentido os profissionais de saúde devem implementar estratégias para estimular mudanças de estilos de vida nos motoristas de transporte de cargas, visando a prevenção primária e secundária / Introduction: Cardiovascular diseases are the main cause of morbidity and mortality in Brazil. Therefore, a study aiming at characterizing the cardiovascular risk profile observed in professional truck drivers who work on Highway Br-116 was carried out. Population and Method: An exploring, descriptive and transversal study with 258 professional truck drivers, social economical information, both body mass index (BMI) and waist circumference evaluations, blood pressure measurement, as well as laboratory test performance: triglycerides, total and fraction cholesterol, and C reactive protein. The risk for cardiovascular diseases was assessed by Framingham scores; alcohol intake by Alcohol Use Disorders Identification-AUDIT; common psychiatric disorders by Self Report Questionnaire-SRQ-20; and angine pectoris by Rose´s test Data were processed in the SPSS system v.7.5, considering that the significance level adopted was 0,05, and univaried and multivaried analyses were used. Results: The characterization of the drivers studied revealed age of 37.5±10.1 years, 91% of them were white, monthly income 1.431,3 ± 644,4 reais (Brazilian currency), 19% were smokers, 55% referred alcohol intake, 74% did not make physical exercises, 14% referred using sleeping inhibitor drugs, professional time 14±10 years and used to drive 782,9±229,6 Km/day. It was observed that 46% of them were overweight and 36% were obese and 58% had altered waist circumference (_ 94 cm) by the anthropometric data. The lab tests showed 33% with total cholesterol level _200 mg/dL, 10% LDLc _160 mg/dL, HDL-c <40 mg/dL 23%, triglycerides over 150 mg/dL 38%, glycemy _110mg/dL 7%, and C reactive protein >0.5 mg/dL 19%. The prevalence of hypertension was 37% and of Metabolic Syndrome, 24%. Rose’s test was positive for 8% of the drivers, Medium/High Framingham scores for 9%, presence of common psychiatric disturbs in 33% and 16% with AUDIT score suggesting intervention and advisory. The logistical regression analysis indicated independent association for the following variables: (OR Odds ratio, CI confidence interval at 95%): 1- Metabolic Syndrome: BMI (OR=1,40 CI 1,192-1,661); the habit of checking the total cholesterol (0,102 IC 0,017-0,589); Medium/high Framingham score (OR=26,389 IC 2,520-276,374); 2-Hypertension: BMI (OR=1,183 IC 1,065-1,314); glycemy (OR=1,039 IC 1,004-1,076); the habit of taking sleeping pills (OR=0,322 IC 0,129-0,801). 3- Total Cholesterol (_ 200 mg/dL): LDL-c (OR=1,157 IC 1,100-1,216); triglycerides (OR=1,012 IC 1,004-1,021). 4- Glycemy (_ 110 mg/dL): BMI (OR=1,153 IC 1,024-1,298); professional time (OR=1,154 IC 1,057-1,259). 5- C reactive protein (>0,5 mg/dL): Medium/high Framingham score (OR=4,692 IC 1,912-11,515). Conclusion: It was observed an expressive presence of cardiovascular risk factors. Therefore health professionals should implement strategies to stimulate changes in truck drivers’ lifestyle, aiming at primary and secondary prevention